Literature DB >> 18926431

Diffusion and perfusion MR imaging of the prostate.

Diederik M Somford1, Jurgen J Fütterer, Thomas Hambrock, Jelle O Barentsz.   

Abstract

Conventional anatomic MR imaging has evolved to a superior modality in the evaluation of prostate carcinoma and is now a widely established technique in the detection and staging of this disease, aiding in clinical decision making on treatment and therapy evaluation. Recent improvements in functional MR techniques, such as diffusion-weighted MR imaging and dynamic contrast-enhanced MR imaging, have greatly increased the impact of MR imaging in prostate cancer. The combination of T2-weighted imaging, diffusion-weighted MR imaging, and dynamic contrast-enhanced MR imaging may overcome the limitations of conventional T2-weighted MR imaging of the prostate and may be able accurately to detect, localize, stage, and grade prostate carcinoma and guide biopsies.

Entities:  

Mesh:

Year:  2008        PMID: 18926431     DOI: 10.1016/j.mric.2008.07.002

Source DB:  PubMed          Journal:  Magn Reson Imaging Clin N Am        ISSN: 1064-9689            Impact factor:   2.266


  19 in total

1.  Increased signal intensity of prostate lesions on high b-value diffusion-weighted images as a predictive sign of malignancy.

Authors:  Michael Quentin; Lars Schimmöller; Christian Arsov; Robert Rabenalt; Gerald Antoch; Peter Albers; Dirk Blondin
Journal:  Eur Radiol       Date:  2013-08-31       Impact factor: 5.315

2.  Impact of field strength and RF excitation on abdominal diffusion-weighted magnetic resonance imaging.

Authors:  Philipp Riffel; Raghuram K Rao; Stefan Haneder; Mathias Meyer; Stefan O Schoenberg; Henrik J Michaely
Journal:  World J Radiol       Date:  2013-09-28

Review 3.  Multiparametric MRI for prostate cancer diagnosis: current status and future directions.

Authors:  Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2019-07-17       Impact factor: 14.432

4.  Magnetic resonance imaging for prostate cancer clinical application.

Authors:  Bing Li; Yong Du; Hanfeng Yang; Yayong Huang; Jun Meng; Dongmei Xiao
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

Review 5.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.

Authors:  Sadhna Verma; Baris Turkbey; Naira Muradyan; Arumugam Rajesh; Francois Cornud; Masoom A Haider; Peter L Choyke; Mukesh Harisinghani
Journal:  AJR Am J Roentgenol       Date:  2012-06       Impact factor: 3.959

6.  Discrimination of prostate carcinoma from benign prostate tissue fragments in vitro by estimating the gross biochemical alterations through Raman spectroscopy.

Authors:  Landulfo Silveira; Kátia Ramos M Leite; Fabricio Luiz Silveira; Miguel Srougi; Marcos Tadeu T Pacheco; Renato Amaro Zângaro; Carlos Augusto Pasqualucci
Journal:  Lasers Med Sci       Date:  2014-03-12       Impact factor: 3.161

7.  Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance.

Authors:  V A Morgan; S F Riches; K Thomas; N Vanas; C Parker; S Giles; N M Desouza
Journal:  Br J Radiol       Date:  2011-01       Impact factor: 3.039

8.  Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging.

Authors:  Valeria Panebianco; Flavio Barchetti; Alessandro Sciarra; Daniela Musio; Valerio Forte; Vincenzo Gentile; Vincenzo Tombolini; Carlo Catalano
Journal:  Eur Radiol       Date:  2013-02-02       Impact factor: 5.315

Review 9.  Prostate cancer and its mimics at multiparametric prostate MRI.

Authors:  J Yu; A S Fulcher; M A Turner; C H Cockrell; E P Cote; T J Wallace
Journal:  Br J Radiol       Date:  2014-03-20       Impact factor: 3.039

Review 10.  Multidisciplinary functional MR imaging for prostate cancer.

Authors:  Jeong Kon Kim; Yun-Jin Jang; Gyunggoo Cho
Journal:  Korean J Radiol       Date:  2009 Nov-Dec       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.